Posted on: 07 December, 2022
Generous funding provided through the Douglas and Lola Douglas scholarship is strengthening evidence around the long term impacts on children born to mothers with obesity and gestational diabetes.
Endocrinologist and Kolling Institute researcher Dr Tessa Weir has been able to continue her valuable research as a result of being awarded the scholarship.
“I am incredibly grateful for t.....
Read more
Category: Cardiovascular and Renal Research, New Treatment, Research Excellence
Posted on: 11 November, 2022
Kolling researcher and Royal North Shore Hospital endocrinologist Associate Professor Sarah Glastras will have a key role in a national effort to improve long-term outcomes for those with diabetes.
The initiative has brought dozens of experts from across the country together under the banner of the Australian Centre for Accelerating Diabetes Innovations Research.
International collaborat.....
Read more
Category: Cardiovascular and Renal Research, New Treatment, Research Excellence
Posted on: 19 October, 2022
Kolling Institute researcher and RNSH Senior Hospital Scientist Dr Anastasia Mihailidou says she was delighted to showcase the district’s work in blood pressure management on the world stage.
Dr Mihailidou, who is head of the Kolling’s Cardiovascular and Hormonal Research Lab, presented at the recent International Society of Hypertension Scientific Meeting in Japan.
Globally renowned aca.....
Read more
Category: Cardiovascular and Renal Research, Research Excellence
Posted on: 17 October, 2022
We would like to congratulate Professors Carol Pollock and Gemma Figtree who have received significant National Health and Medical Research Council Investigator Grants.
Despite a tremendously competitive field, both clinician/researchers have been awarded $2 million to progress their world-leading research and improve long-term patient outcomes.
The announcement highlights the experience.....
Read more
Category: Cardiovascular and Renal Research, Research Excellence
Posted on: 16 September, 2022
Improved accessibility to a treatment for kidney disease has been welcomed by Kolling Institute researcher and Royal North Shore Hospital clinician Professor Carol Pollock.
Forxiga (dapagliflozin), an oral medicine which can help slow the progression of proteinuric chronic kidney disease, has now been listed on the Pharmaceutical Benefits Scheme.
The listing aims to help those with the c.....
Read more
Category: Cardiovascular and Renal Research, New Treatment
Posted on: 26 August, 2022
With a disturbing number of people losing their lives to heart disease each year, researchers have launched the first study of its kind using MRI technology to broaden our understanding of the link between cardiovascular disease and sleep apnoea.
The project has been made possible following funding from the Ramsay Research Grant Program, and will involve clinician researchers from Northe.....
Read more
Category: Cardiovascular and Renal Research, Research Excellence
Posted on: 10 August, 2022
We may soon have a safer approach to diagnosing and measuring the progression of chronic kidney disease following new research by the team from the Kolling Institute’s Renal Research Laboratory.
The condition is a global health issue, which now affects more than 13 per cent of the worldwide population.
Chronic kidney disease is a progressive disease that leads to end-stage kidney failur.....
Read more
Category: Cardiovascular and Renal Research, Research Excellence
Posted on: 15 March, 2022
Research from the University of Sydney and Royal North Shore Hospital provides insights into cardiac risk among footballers of masters age (35 years and older), an increasingly popular pastime.
In what is believed to be the first study to assess cardiac knowledge and beliefs in this higher-risk amateur football group, researchers have found that one in five players experienced one or mor.....
Read more
Category: Cardiovascular and Renal Research, Research Excellence
Posted on: 20 December, 2021
The largest study of its kind in Australia has found patients with a history of heart failure are three times more likely to die from COVID-19.
Launched last year at the outset of the pandemic, the AUS-COVID trial is investigating those who are most at risk from COVID-19 in Australia. To date, it has assessed hundreds of patients in 21 hospitals across the country.
The study confirmed ea.....
Read more
Category: Cardiovascular and Renal Research, Research Excellence
Posted on: 18 October, 2021
Just over two years ago, Ian Hutchinson (Hutch) was cycling with a friend on Sydney’s northern beaches, taking part in an activity he regularly enjoyed with his mate. But that morning was to have a life-changing impact, with Hutch suffering a sudden cardiac arrest midway through the ride.
It was only the quick thinking of his friend Don MacKee and a group of bystanders who called triple .....
Read more
Category: Cardiovascular and Renal Research